柳药集团(603368) - 2024 Q1 - 季度财报

Financial Performance - The company achieved operating revenue of CNY 5.77 billion in Q1 2024, representing a year-on-year increase of 8.25%[6] - Net profit attributable to shareholders reached CNY 300.35 million, up 15.04% compared to the same period last year[6] - The basic earnings per share (EPS) was CNY 0.83, reflecting a growth of 15.28% year-on-year[3] - Total operating revenue for Q1 2024 reached CNY 5,774,668,302.52, an increase of 8.3% compared to CNY 5,334,761,606.27 in Q1 2023[23] - Net profit for Q1 2024 was CNY 312,798,274.35, representing a 15.7% increase from CNY 270,305,830.30 in Q1 2023[24] - The net profit attributable to shareholders of the parent company was CNY 300,349,057.76, compared to CNY 261,072,142.03 in the same period last year, marking a 15.1% growth[25] - Earnings per share for Q1 2024 were CNY 0.83, up from CNY 0.72 in Q1 2023[25] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to CNY 20.65 billion, an increase of 2.41% from the end of the previous year[4] - The company's equity attributable to shareholders rose to CNY 6.92 billion, marking a 4.54% increase from the previous year[4] - The company's total liabilities increased to CNY 13,269,216,738.21 in Q1 2024 from CNY 13,095,714,302.96 in Q1 2023[20] - Total equity rose to CNY 7,376,537,741.83 in Q1 2024, compared to CNY 7,063,739,467.48 in Q1 2023[20] Revenue Segmentation - The wholesale segment generated CNY 469.88 million in revenue, a 6.22% increase, contributing 81.76% to total revenue[8] - Retail revenue increased by 20.04% to CNY 78.14 million, accounting for 13.60% of total revenue[8] - The industrial segment reported revenue of CNY 26.69 million, up 8.66%, contributing 4.64% to total revenue[8] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,719[12] - The largest shareholder, Zhu Chaoyang, holds 27.89% of shares, totaling 101,032,795 shares, with 33,890,000 shares pledged[12] Capital Raising and Financing - The company plans to issue A-shares to specific targets, with a total of 36,842,105 shares at a price of 19.00 RMB per share, raising approximately 700 million RMB[14] - The company raised CNY 1,688,140,000.00 through borrowings in Q1 2024, compared to CNY 1,135,565,732.16 in Q1 2023, indicating a 49% increase in financing activities[29] - Total cash outflows from financing activities were CNY 2,460,431,204.31, up from CNY 1,419,294,241.11 in the previous year, leading to a net cash flow from financing activities of negative CNY 470,247,573.62[29] Cash Flow Management - The total cash flow from operating activities for Q1 2024 was not provided in the extracted data, indicating a need for further details on cash flow management[26] - In Q1 2024, the company reported cash inflows from operating activities of CNY 5,434,684,097.45, an increase of 19% compared to CNY 4,568,493,101.08 in Q1 2023[28] - The net cash flow from operating activities was negative CNY 533,392,772.73, slightly improved from negative CNY 542,426,332.72 in the same period last year[28] - Cash outflows for investing activities totaled CNY 47,323,669.14, down from CNY 57,832,791.59 in Q1 2023, resulting in a net cash flow from investing activities of negative CNY 44,604,426.41[29] - The ending balance of cash and cash equivalents was CNY 1,600,704,460.59, a decrease from CNY 1,885,881,118.63 at the end of Q1 2023[29] Research and Development - Research and development expenses for Q1 2024 were CNY 6,819,252.74, slightly down from CNY 7,756,228.00 in Q1 2023[24] Market Expansion - The company has completed the filing of over 470 varieties for its traditional Chinese medicine granules project as of the end of Q1 2024[6] - The company is actively expanding its market presence outside Guangxi through partnerships with major chain pharmacies and distributors[6] Tax and Financial Expenses - The company paid CNY 149,632,479.49 in taxes, which is an increase from CNY 122,103,608.32 in the previous year, representing a 22.6% rise[28] - The company reported a financial expense of CNY 54,531,137.89 in Q1 2024, an increase from CNY 47,693,343.61 in Q1 2023[24]